The Proteomics Core Facility (PCF) at Oslo University Hospital - Rikshospitalet and University of Oslo provides proteomic service to all research groups in the HSØ region in need of it. The main areas of expertise of PCF are in protein identification and quantification, and in the analysis of proteins' post-translational modifications and protein interactions. The unit has special expertise with proteomics applied to immunology and cell signaling research, as well as in clinical proteomics applications. Proteomics methods, techniques, and instruments are under very active development world-wide. PCF collaborates with several research groups locally and internationally to develop and set-up new proteomics techniques that can be later on taken into the list of services provided by the unit. 

PCF is a member of the National Network of Advanced Proteomics Infrastructure (NAPI), which is funded by the Research Council of Norway. Both the NAPI Project Manager (Tuula Nyman) and NAPI Administrative Manager (Jorunn Stamnas) are based at PCF.  

Recent news:

Dr Tuula Nyman is the Project Manager at NAPI. In this profile article, Tuula discusses what NAPI will bring to proteomics research in Norway, her career highlights so far, and the Swedish Royal family performing mass spectrometry experiments.

A new collaborative study by researchers in Finland and Norway – including PCF head Tuula Nyman – provides novel insights into how mycobacteria can escape elimination by antibiotics. These findings could have important implications for treating mycobacteria-driven diseases such as Tuberculosis.

Do gluten-free diets provide a cure-all for coeliac disease? Proteomics-based research suggests not?

Coeliac disease is a highly prevalent disorder characterised by a harmful immune reaction to dietary gluten proteins in the upper small intestine. It is a genetically-linked condition that runs in families, with certain types of the Human Leukocyte Antigen (HLA) genes (involved in regulating the immune system) known to increase an individual’s risk of developing the disorder. The disease is caused when CD4+ T-cells in a patient respond to gluten, mounting an immune reaction that causes intestinal damage.